Eli Lilly › Eli Lilly (NYSE: LLY) has been a terrific stock to own over the past 15 years; it has consistently outperformed ...

Eli Lilly's GLP-1 drugs fuel massive growth, with potential $60bn+ annual revenue. Check out why I remain bullish long term ...

Eli Lilly and Company’s LLY stock has declined 5.1% so far this month, despite announcing strong second-quarter results on ...

Shares of Eli Lilly (LLY) are testing a resistance level. If they can break through this resistance, a large more higher may follow.

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

So why did Lilly's share price sink like a brick today ... of 12% with an oral drug could still be appealing to many patients and physicians. Sometimes stock sell-offs present great opportunities. I ...

Eli Lilly stock dropped more than 20% due to underwhelming results from its drug trials. However, a rebound may be underway.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

Those following along with Eli Lilly and Company (NYSE:LLY) will no doubt be intrigued by the recent purchase of shares by David Ricks, Chairman of the company, who spent a stonking US$1.1m on stock ...

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other European countries, in response to President Trump's push to normalize pricing ...